SCHEMBL5728067

SCHEMBL5728067

c1cnc2c(c1)cc1cnccn12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.40
NCOA3 Q9Y6Q9 1/20 0.40
CYP11B1 P15538 2/20 0.36
CYP11B2 P19099 2/20 0.36
CYP3A4 P08684 4/20 0.36
CYP2A6 P11509 4/20 0.36
PARP1 P09874 1/20 0.36
PDE2A O00408 1/20 0.35
PDE6D O43924 1/20 0.35
PDE8A O60658 1/20 0.35
PDE5A O76074 1/20 0.35
PDE9A O76083 1/20 0.35
PDE8B O95263 1/20 0.35
PDE6A P16499 1/20 0.35
PDE6G P18545 1/20 0.35
PDE4A P27815 1/20 0.35
PDE6B P35913 1/20 0.35
PDE6C P51160 1/20 0.35
PDE1A P54750 1/20 0.35
PDE1B Q01064 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30990399 0.77 MKNK2 (0.44) CYP19A1
SCHEMBL38659921 0.75 CYP19A1 (0.40) KDM4ECYP11B1CYP11B2CYP3A4CYP2A6
SCHEMBL4756741 0.75 CYP19A1 (0.40) KDM4ECYP11B1CYP11B2CYP3A4CYP2A6
SCHEMBL2960574 0.74 NCOA3 (0.37) KDM4ENCOA3CYP11B1CYP11B2CYP3A4
SCHEMBL29895259 0.70 CYP11B2 (0.41) KDM4ECYP11B2CYP3A4PARP1CYP2C19
SCHEMBL9430919 0.70 CYP11B2 (0.38) KDM4ECYP11B1CYP11B2CYP2A6PARP1
SCHEMBL1370460 0.69 PARP1 (0.42) KDM4ECYP3A4PARP1PDE2APDE6D
SCHEMBL30405693 0.67 CDC7 (0.51) KDM4ECYP3A4CYP2A6PARP1CYP2E1
SCHEMBL415753 0.67 CDC7 (0.51) KDM4ECYP3A4CYP2A6PARP1CYP2E1
SCHEMBL1368544 0.66 PARP1 (0.42) KDM4ECYP3A4PARP1PDE2APDE6D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026084957-A1 TRICYCLIC HETEROARYL COMPOUNDS USEFUL FOR ENHANCING INNATE IMMUNE RESPONSES ASSEMBLY BIOSCIENCES, INC. (US) 2026-04-23 WO disclosed
EP-1641796-A1 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY F. HOFFMANN-LA ROCHE AG (CH) 2006-04-05 EP disclosed
WO-2005000849-A1 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY F. HOFFMANN-LA ROCHE AG (CH) 2005-01-06 WO disclosed